U01DK143500
Cooperative Agreement
Overview
Grant Description
Driving next generation UPR inhibitory kinase inhibitors for T1D - Project summary/abstract
Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by hyperglycemia due to progressive immune-mediated destruction of pancreatic beta cells.
Recent work from our laboratories has shown that hyperactivation of the unfolded protein response (UPR) to ER stress in the immune-targeted beta cells may be a critical early event in the development of T1D.
We have developed novel pharmacological reagents called ‘PAIRs’ that allow us to manipulate components of the UPR.
Importantly, first-generation versions of small molecules delivered to NOD mice can efficaciously prevent and even reverse diabetes in this T1D model.
Thus, in this collaborative grant we will capitalize on the complementary expertise of the investigators to optimize these next-generation “PAIR” molecules for potency and selectivity, conduct proof-of-concept studies using human islets (ex vivo and in transplanted mice), and perform key enabling steps needed to advance these candidates further into the clinic for treating human patients with T1D.
Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by hyperglycemia due to progressive immune-mediated destruction of pancreatic beta cells.
Recent work from our laboratories has shown that hyperactivation of the unfolded protein response (UPR) to ER stress in the immune-targeted beta cells may be a critical early event in the development of T1D.
We have developed novel pharmacological reagents called ‘PAIRs’ that allow us to manipulate components of the UPR.
Importantly, first-generation versions of small molecules delivered to NOD mice can efficaciously prevent and even reverse diabetes in this T1D model.
Thus, in this collaborative grant we will capitalize on the complementary expertise of the investigators to optimize these next-generation “PAIR” molecules for potency and selectivity, conduct proof-of-concept studies using human islets (ex vivo and in transplanted mice), and perform key enabling steps needed to advance these candidates further into the clinic for treating human patients with T1D.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
San Francisco,
California
94143
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 291% from $816,325 to $3,194,538.
San Francisco Regents Of The University Of California was awarded
Next-Gen UPR Inhibitory Kinase Inhibitors for T1D Treatment
Cooperative Agreement U01DK143500
worth $3,194,538
from the National Institute of Diabetes and Digestive and Kidney Diseases in August 2025 with work to be completed primarily in San Francisco California United States.
The grant
has a duration of 3 years 10 months and
was awarded through assistance program 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
The Cooperative Agreement was awarded through grant opportunity Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 7/6/26
Period of Performance
8/1/25
Start Date
6/30/29
End Date
Funding Split
$3.2M
Federal Obligation
$0.0
Non-Federal Obligation
$3.2M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for U01DK143500
Transaction History
Modifications to U01DK143500
Additional Detail
Award ID FAIN
U01DK143500
SAI Number
U01DK143500-3134388765
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NK00 NIH National Institute of Diabetes and Digestive and Kidney Diseases
Funding Office
75NK00 NIH National Institute of Diabetes and Digestive and Kidney Diseases
Awardee UEI
KMH5K9V7S518
Awardee CAGE
4B560
Performance District
CA-11
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Modified: 7/6/26